Abstract PS6-35: Real world outcomes in elderly women with HER2 positive advanced breast cancer

• Published in: Cancer research (Chicago, Ill.) Ill.), 2021-02, Vol.81 (4_Supplement), p.PS6-35-PS6-35
• Main Authors: Evans, Nicole, Anton, Angelyn, Wong, Rachel, Lok, Sheau Wen, De Boer, Richard, Malik, Laeeq, Greenberg, Sally, Yeo, Belinda, Nott, Louise, Richardson, Gary, Collins, Ian M, Torres, Javier, Barnett, Frances, Gibbs, Peter, Devitt, Bianca
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.SABCS20-PS6-35

BackgroundThe development of anti-human epidermal growth factor receptor 2 (HER2) therapies has significantly improved disease outcomes in patients with HER2-positive advanced breast cancer (ABC). However, elderly patients are persistently under-represented in clinical trials, with only 2.4% of patients aged ≥75 years in the pivotal CLEOPATRA study. Despite a lack of research addressing treatment outcomes in elderly patients, advanced age at diagnosis is associated with a greater likelihood of receiving no initial systemic therapy for de novo metastatic breast cancer. Studies have also shown that older women diagnosed with metastatic breast cancer have a poorer prognosis and shorter life expectancy. We examined treatment patterns and outcomes in an elderly (defined as ≥70) ‘real world’ Australian population. MethodsData was extracted from the Treatment of Advanced Breast Cancer in the HER2-positive Australian Patient (TABITHA) multi-site clinical registry, and patients stratified according to age (